Vitamin K Inhibitors
1 drugsAbout Vitamin K
Vitamin K is a group of fat-soluble vitamins essential for blood coagulation, bone metabolism, and cell growth regulation. It acts as a cofactor for gamma-glutamyl carboxylase, modifying clotting factors and influencing other biological processes.
Vitamin K's established physiological importance suggests that modulating its activity could offer therapeutic benefits. Currently, there is no genetic evidence directly linking Vitamin K variations to disease susceptibility.
There is one FDA-approved drug, VITAMIN K1 (Pfizer), a small molecule indicated in immunology. VITAMIN K1 was first approved in 1983 and has 10 indications.
Top Vitamin K Drugs
The competitive landscape is highly concentrated, with Pfizer holding the only approved drug.
The lack of competitors presents an opportunity for new entrants, but also indicates potential market challenges.
Vitamin K Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Vitamin K, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could create differentiation in the Vitamin K space.
Vitamin K Clinical Trials 17 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Vitamin K. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 1 | 100% |
| Phase 2 | 3 | 3 | 0 | 0 | 100% |
| Phase 3 | 3 | 1 | 1 | 1 | 50% |
| Phase 4 | 4 | 3 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Vitamin K Drug Approval Timeline (1983 - 1983)
The approval timeline shows that the first and most recent drug approval was VITAMIN K1 in 1983.
The stagnant approval timeline suggests a saturated market or challenges in developing new Vitamin K-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 15 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Vitamin K. A trial counts if an approved drug acting on Vitamin K is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.